HI SB983

Requires injured employees and physicians to execute a written informed consent agreement before prescribing opioids if treatment exceeds three months, benzodiazepines and opioids are prescribed together, or the dose exceeds ninety morphine equivalent doses.

Mandates the Department of Health's harm reduction services branch develop a template informed consent agreement including overdose risk discussion, naloxone co-prescribing, non-opioid alternatives, functional treatment goals, risk assessments, urine drug screening at least twice yearly, and psychologist/psychiatrist referral if therapy continues beyond six months.

Limits reimbursement for schedule II controlled substances dispensed by physicians to an initial seven-day supply commencing upon first visit, with injured employee and physician engaging in informed consent process first.

Caps compounded prescription drug supplies to thirty days maximum per prescription with a payment limit (amount unspecified) per thirty-day period.

Effective July 1, 2050, with the opioid therapy informed consent agreement template required for use within thirty days of the effective date.